Combined decongestive therapy and reduction of pain and heaviness in patients with breast cancer-related lymphedema

2019 ◽  
Vol 27 (10) ◽  
pp. 3805-3811 ◽  
Author(s):  
Zahra Sheikhi Mobarakeh ◽  
Parisa Mokhtari-Hesari ◽  
Masomeh Lotfi-Tokaldany ◽  
Ali Montazeri ◽  
Mahnaz Heidari ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Reduction Of Pain ◽  
Breast Cancer Related Lymphedema ◽  
Combined Decongestive Therapy ◽  
Decongestive Therapy

scholarly journals Combined-complex Decongestive Therapy Reduces Volume and Improves Quality of Life and Functional Status in Patients with Breast Cancer-related Lymphedema

2020 ◽  
Author(s):  
Pinar Borman ◽  
Aysegul Yaman ◽  
Sina Yasrebi ◽  
Adeviye Pinar Inanli
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Functional Status ◽  
Excess Volumes ◽  
Complex Decongestive Therapy ◽  
Eortc Qlq C30 ◽  
Breast Cancer Related Lymphedema ◽  
Eortc Qlq ◽  
Decongestive Therapy

Abstract Background: The aim of this study was to evaluate the effects of complex decongestive therapy (CDT) in patients with breast cancer-related lymphedema (BCRL), in regard to volume reduction, functional status and quality of life (QoL).Methods: Fifty patients with unilateral BCRL were included. The demographic variables focusing on lymphedema were recorded. All patients received combined phase 1 CDT including skin care, manual lymphatic drainage, multilayer bandaging and supervised exercises, five times a week for three weeks, as a total of 15 sessions. Patients were assessed by limb volumes and excess volumes according to geometric approximation derived from serial circumference-measurements of the limb, prior and at the end of third week. The functional disability was evaluated by quick disability of arm, shoulder and hand questionnaire (DASH). Quality of life was assessed by the European Organization forResearch and Treatment of Cancer Core Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) and its breast cancer module (EORTC-QLQ-BR23­).Results: Fifty females with mean age of 53.22±11.2 years were included. The median duration of lymphedema was 12 months. There were 22 patients in stage1, 26 in stage2 and 2 patients in stage3. The mean baseline limb and excess volumes were significantly decreased at the end of therapies (3262±753cm³ vs 2943±646.6cm³ and 31.36±16.5% vs 19.12±10.4%, p=0.000,respectively). The DASH and EORTC-QLQ-C30 and BR23 scores were also decreased significantly (p<0.05). The improvements in volumes were related negatively with the duration of lymphedema,and the stage of lymphedema. Conclusion: In conclusion phase 1CDT in a combined manner performed daily for 3 weeks, greatly reduces the volumes as well as improves the disability and QoL, especially when performed earlier.

scholarly journals Combıned-Complex Decongestıve Therapy Reduces Volume And Improves Quality Of Lıfe And Functıonal Status In Patıents Wıth Breast Cancer-Related Lymphedema

2020 ◽  
Author(s):  
Pinar Borman ◽  
Aysegul Yaman ◽  
Sina Yasrebi ◽  
Adeviye Pinar Inanli
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Functional Status ◽  
Excess Volumes ◽  
Complex Decongestive Therapy ◽  
Eortc Qlq C30 ◽  
Breast Cancer Related Lymphedema ◽  
Eortc Qlq ◽  
Decongestive Therapy

Abstract Background: The aim of this study was to evaluate the effects of complex decongestive therapy (CDT) in patients with breast cancer-related lymphedema (BCRL), in regard to volume reduction, functional status and quality of life (QoL).Methods: Fifty patients with unilateral BCRL were included. The demographic variables focusing on lymphedema were recorded. All patients received combined phase 1 CDT including skin-care, manual lymphatic drainage, multilayer bandaging and supervised exercises, five times a week for three weeks, as a total of 15 sessions. Patients were assessed by limb volumes and excess volumes according to geometric approximation derived from serial circumference-measurements of the limb, prior and at the end of third week. The functional disability was evaluated by quick disability of arm, shoulder and hand questionnaire (DASH). Quality of life was assessed by the European Organization for Research and Treatment of Cancer Core Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) and its breast cancer module (EORTC-QLQ-BR23­).Results: Fifty females with mean age of 53.22±11.2 years were included. The median duration of lymphedema was 12 months. There were 22 patients in stage1, 26 in stage2 and 2 patients in stage3. The mean baseline limb and excess volumes were significantly decreased at the end of therapies (3262±753cm³ vs 2943±646.6cm³ and 31.36±16.5% vs 19.12±10.4%, p=0.000,respectively). The DASH and EORTC-QLQ-C30 and BR23 scores were also decreased significantly (p<0.05). The improvements in volumes were related negatively with the duration of lymphedema,and the stage of lymphedema. Conclusion: In conclusion phase 1CDT in a combined manner performed daily for 3 weeks, greatly reduces the volumes as well as improves the disability and QoL, especially when performed earlier.Trial Registration: 'retrospectively registered’

Sign in / Sign up

Export Citation Format

Share Document